Signet ring cell intrahepatic cholangiocarcinoma

Summary

Signet ring cell intrahepatic cholangiocarcinoma (MONDO:0004346) is a disease. A subtype of extrahepatic bile duct signet ring cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	signet ring cell intrahepatic cholangiocarcinoma
Mondo ID	MONDO:0004346
DOID	DOID:7733
NCIT	C41619
UMLS	C1519321
MedGen	276815
GARD	0023949
Is cancer (heuristic)	no

Also known as: signet Ring cell intrahepatic cholangiocarcinoma

Disease family

Classification path: disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › bile duct carcinoma › extrahepatic bile duct carcinoma › extrahepatic bile duct adenocarcinoma › extrahepatic bile duct signet ring cell carcinoma › signet ring cell intrahepatic cholangiocarcinoma

Related subtypes (1): ampullary signet ring cell adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.